Clinical Trial: Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828211) titled 'Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD' on Jan. 15.

Brief Summary: 1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD).

2. To evaluate the safety of long-term use of trans-resveratrol in an amount of 500 mg per day.

3. To develop modern measures to influence the development of CHF in women of this group

Study Start Date: Sept. 09, 2024

Study Type: INTERVENTIONAL

Condition: Heart Failur...